Contact Us
|
Search
|
Site Map
About Us
Crucell at a Glance
Our History
Mission & Strategy
Guiding Principles
Crucell Worldwide
Management
Corporate Governance
Technology
PER.C6® Technology
Vaccine Technology
Protein Technology
Products
Hepavax-Gene®
Quinvaxem™
Epaxal®
Vivotif®
Inflexal® V
MoRu-Viraten®
Dukoral®
Questions About Products
R&D
Discovery Programs
Development Programs
Clinical Trials
Scientific Publications
Partners
Strategic Partners
Marketing & Sales Partners
R&D Partners & Licensees
Partnering Opportunities
Investors
Corporate Profile
Share Information
Financial Information
Press Releases
Event Calendar
Presentations
Shareholder Services
Investor Relations Contacts
Media
Press Releases
Media Kit
Image Library
Useful Links
Glossary
Media Contacts
Careers
Vacancies
Internships
Benefits & Rewards
Our Team
Hidden
10 year anniversary Inflexal V
Euronext:
€
NASDAQ:
$
SWX:
CHF
11.82
0.16
(15 minute delay)
18.23
0.35
(15 minute delay)
18.65
-0.80
(15 minute delay)
More information on our share performance
6 May 2008
Crucell to Release Q1 2008 Earnings on Tuesday, May 13, 2008
29 April 2008
Crucell Announces STAR® Research License Agreement with Toyobo Gene Analysis Co. LTD.
9 April 2008
Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
First Quarter Results 2008 Conference Call
Tuesday, May 13 at 14.00 PM (CET)
Link to live audiowebcast with presentation slides
Crucell introduces new corporate logo
February 18, 2008
Read more
Investor and Analyst Day, London
Wednesday, March 12 at 10.00 AM (CET)
Link to videowebcast with presentation slides
Fourth Quarter and Full Year Results 2007 Conference Call
Tuesday, February 12 at 14.00 PM (CET)
Link to live audiowebcast with presentation slides
Served
by
MoveNext
© Crucell 2006 |
Disclaimer